Search
Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating
go.drugbank.com/bio_entities/BE0000044TargetHumansAlso plays a role in the regulation of the endocytic trafficking of EGFR (By similarity) … Catalyzes the NAD(P)(+)-dependent oxidative decarboxylation of the C4 methyl groups of 4-alpha-carboxysterols in post-squalene cholesterol biosynthesis (By similarity).
Polypeptides: Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylatingLong-chain-fatty-acid--CoA ligase 4
go.drugbank.com/bio_entities/BE0000996TargetHumansCatalyzes the conversion of long-chain fatty acids to their active form acyl-CoA for both synthesis of cellular lipids, and degradation via beta-oxidation (PubMed:21242590, PubMed:22633490, PubMed:24269233, PubMed:31061331, PubMed:387201...
Polypeptides: Long-chain-fatty-acid--CoA ligase 4Synonyms: LACS 4, Long-chain acyl-CoA synthetase 4Sodium channel protein type 4 subunit alpha
go.drugbank.com/bio_entities/BE0002083TargetTransporterHumansPore-forming subunit of Nav1.4, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes.
Polypeptides: Sodium channel protein type 4 subunit alphaVery long chain fatty acid elongase 4
go.drugbank.com/bio_entities/BE0002247EnzymeTargetHumansMay play a critical role in early brain and skin development
Polypeptides: Very long chain fatty acid elongase 4Synonyms: ELOVL FA elongase 4, ELOVL fatty acid elongase 4Calcium-activated potassium channel subunit beta-4
go.drugbank.com/bio_entities/BE0004424TargetHumansRegulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Decreases the gating kinetics and calcium se...
Polypeptides: Calcium-activated potassium channel subunit beta-4Synonyms: Slo-beta-4, K(VCA)beta-4Mitogen-activated protein kinase kinase kinase 4
go.drugbank.com/bio_entities/BE0009468TargetHumansComponent of a protein kinase signal transduction cascade. Activates the CSBP2, P38 and JNK MAPK pathways, but not the ERK pathway. Specifically phosphorylates and activates MAP2K4 and MAP2K6
Polypeptides: Mitogen-activated protein kinase kinase kinase 4Synonyms: MEKK 4, MEK kinase 4Myosin light chain kinase family member 4
go.drugbank.com/bio_entities/BE0009494TargetHumansPolypeptides: Myosin light chain kinase family member 4Insulin-like growth factor-binding protein 4
go.drugbank.com/bio_entities/BE0009660CarrierHumansIGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors
Polypeptides: Insulin-like growth factor-binding protein 4Synonyms: IBP-4, IGFBP-4Sphingolipid delta(4)-desaturase/C4-monooxygenase DES2
go.drugbank.com/bio_entities/BE0015894EnzymeHumansBifunctional enzyme which acts both as a sphingolipid delta(4)-desaturase and a sphingolipid C4-monooxygenase
Polypeptides: Sphingolipid delta(4)-desaturase/C4-monooxygenase DES2Synonyms: Sphingolipid 4-desaturaseKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. … It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332]
Categories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsSynonyms: 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone, 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone